G. Monfette

1.2k total citations
17 papers, 886 citations indexed

About

G. Monfette is a scholar working on Pulmonary and Respiratory Medicine, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, G. Monfette has authored 17 papers receiving a total of 886 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 11 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Molecular Biology. Recurrent topics in G. Monfette's work include Prostate Cancer Treatment and Research (17 papers), Hormonal and reproductive studies (11 papers) and Prostate Cancer Diagnosis and Treatment (7 papers). G. Monfette is often cited by papers focused on Prostate Cancer Treatment and Research (17 papers), Hormonal and reproductive studies (11 papers) and Prostate Cancer Diagnosis and Treatment (7 papers). G. Monfette collaborates with scholars based in Canada and Germany. G. Monfette's co-authors include Jean Emond, Fernand Labrie, A. Bèlanger, A. Dupont, Yves Lacourcière, M. Giguère, J.M. Husson, A.T.A. Fazekas, Jean‐Pierre Raynaud and Y. Lacoursière and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Endocrine Reviews and Cancer and Metastasis Reviews.

In The Last Decade

G. Monfette

16 papers receiving 809 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Monfette Canada 10 673 472 154 150 112 17 886
A Dupont Canada 10 457 0.7× 340 0.7× 145 0.9× 124 0.8× 64 0.6× 26 695
Jean Emond Canada 14 1.0k 1.5× 516 1.1× 196 1.3× 168 1.1× 140 1.3× 27 1.3k
J.M. Husson Canada 6 405 0.6× 284 0.6× 93 0.6× 86 0.6× 73 0.7× 7 511
Jerry Albert United States 15 464 0.7× 421 0.9× 98 0.6× 140 0.9× 70 0.6× 23 623
Thomas J. Worgul United States 13 181 0.3× 257 0.5× 131 0.9× 384 2.6× 102 0.9× 19 730
Naohide Sato Japan 11 384 0.6× 170 0.4× 230 1.5× 146 1.0× 95 0.8× 24 601
John E. McNeal United States 8 465 0.7× 95 0.2× 178 1.2× 256 1.7× 112 1.0× 9 671
Y. Lacoursière Canada 4 273 0.4× 183 0.4× 52 0.3× 46 0.3× 48 0.4× 7 354
Piroska Bujnovszky United States 10 273 0.4× 136 0.3× 202 1.3× 201 1.3× 68 0.6× 10 512
Stephen M. Edwards United Kingdom 15 298 0.4× 105 0.2× 538 3.5× 147 1.0× 281 2.5× 22 933

Countries citing papers authored by G. Monfette

Since Specialization
Citations

This map shows the geographic impact of G. Monfette's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Monfette with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Monfette more than expected).

Fields of papers citing papers by G. Monfette

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Monfette. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Monfette. The network helps show where G. Monfette may publish in the future.

Co-authorship network of co-authors of G. Monfette

This figure shows the co-authorship network connecting the top 25 collaborators of G. Monfette. A scholar is included among the top collaborators of G. Monfette based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Monfette. G. Monfette is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Dupont, A., Fernand Labrie, L. Cusan, et al.. (1992). Combination Therapy with Flutamide and Castration (Orchiectomy or LH-RH Agonist) in Untreated Patients with Advanced Prostate Cancer. Recent results in cancer research. 124. 43–54. 1 indexed citations
2.
Labrie, Fernand, A. Dupont, L. Cusan, et al.. (1990). Combination therapy with flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer: 7-year clinical experience. The Journal of Steroid Biochemistry and Molecular Biology. 37(6). 943–950. 12 indexed citations
3.
Labrie, Fernand, L. Cusan, Yves Lacourcière, et al.. (1989). Combination therapy with flutamide and castration: its benefits at various stages of prostate cancer.. PubMed. 303. 161–7. 1 indexed citations
4.
Labrie, Fernand, A. Dupont, M. Giguère, et al.. (1988). Benefits of Combination Therapy with Flutamide in Patients Relapsing after Castration. British Journal of Urology. 61(4). 341–346. 50 indexed citations
5.
Labrie, Fernand, M. Giguère, Yves Lacourcière, et al.. (1988). Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.. PubMed. 260. 41–62. 6 indexed citations
6.
Labrie, Fernand, A Dupont, L. Cusan, et al.. (1988). Combination therapy with flutamide and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide in stage C and D prostate cancer: today's therapy of choice--rationale and 5-year clinical experience.. PubMed. 262. 11–63. 2 indexed citations
7.
Labrie, Fernand, L. Cusan, Isabel A Lüthy, et al.. (1987). Combination therapy in stage C and D prostatic cancer: rationale and five-year clinical experience. Cancer and Metastasis Reviews. 6(4). 615–636. 4 indexed citations
8.
Labrie, Fernand, A. Dupont, M. Giguère, et al.. (1987). Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients. Journal of Steroid Biochemistry. 27(1-3). 525–532. 16 indexed citations
9.
Labrie, Fernand, A. Dupont, M. Giguère, et al.. (1986). Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer. Journal of Steroid Biochemistry. 25(5). 877–883. 14 indexed citations
10.
Labrie, Fernand, A Dupont, A. Bèlanger, et al.. (1986). Treatment of Prostate Cancer with Gonadotropin-Releasing Hormone Agonists. Endocrine Reviews. 7(1). 67–74. 141 indexed citations
11.
Labrie, Fernand, et al.. (1986). [Combined anti-androgen treatment in adenocarcinoma of the prostate: first use of a new therapeutically efficacious principle in hormone-dependent cancer].. PubMed. 20(2). 98–106. 4 indexed citations
12.
Labrie, Fernand, A. Bèlanger, Y. Lacoursière, et al.. (1985). Antiandrogènes et agonistes de LHRH dans le traitement du cancer de la prostate. médecine/sciences. 1(8). 435–435. 1 indexed citations
13.
Labrie, Fernand, A. Dupont, A. Bèlanger, et al.. (1985). Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival. Journal of Steroid Biochemistry. 23(5). 833–841. 123 indexed citations
14.
Labrie, Fernand, A. Dupont, A. Bélanger, Jean Emond, & G. Monfette. (1984). Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.. Proceedings of the National Academy of Sciences. 81(12). 3861–3863. 45 indexed citations
15.
Labrie, Fernand, A. Dupont, A. Bèlanger, et al.. (1983). New hormonal treatment in cancer of the prostate: Combined administration of an LHRH agonist and an antiandrogen. Journal of Steroid Biochemistry. 19(1). 999–1007. 35 indexed citations
16.
Labrie, Fernand, A. Dupont, A. Bèlanger, et al.. (1983). New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens. The Prostate. 4(6). 579–594. 219 indexed citations
17.
Labrie, Fernand, A. Dupont, A. Bèlanger, et al.. (1982). New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.. PubMed. 5(4). 267–75. 212 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A Dupont Breakdown of academic impact, for papers by Jean Emond Breakdown of academic impact, for papers by J.M. Husson Breakdown of academic impact, for papers by Jerry Albert Breakdown of academic impact, for papers by Thomas J. Worgul Breakdown of academic impact, for papers by Naohide Sato Breakdown of academic impact, for papers by John E. McNeal Breakdown of academic impact, for papers by Y. Lacoursière Breakdown of academic impact, for papers by Piroska Bujnovszky Breakdown of academic impact, for papers by Stephen M. Edwards
Rankless by CCL
2026